Steering Tumor Progression Through the Transcriptional Response to Growth Factors and Stroma

Overview

Journal FEBS Lett

Specialty Biochemistry

Date 2014 May 31

PMID 24873881

Citations 5

Authors

Morris E Feldman

Yosef Yarden

Affiliations

Soon will be listed here.

Abstract

Tumor progression can be understood as a collaborative effort of mutations and growth factors, which propels cell proliferation and matrix invasion, and also enables evasion of drug-induced apoptosis. Concentrating on EGFR, we discuss downstream signaling and the initiation of transcriptional events in response to growth factors. Specifically, we portray a wave-like program, which initiates by rapid disappearance of two-dozen microRNAs, followed by an abrupt rise of immediate early genes (IEGs), relatively short transcripts encoding transcriptional regulators. Concurrent with the fall of IEGs, some 30-60 min after stimulation, a larger group, the delayed early genes, is up-regulated and its own fall overlaps the rise of the final wave of late response genes. This late wave persists and determines long-term phenotype acquisition, such as invasiveness. Key regulatory steps in the orderly response to growth factors provide a trove of potential oncogenes and tumor suppressors.

Citing Articles

TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.

Uribe M, Dahlhoff M, Batra R, Nataraj N, Haga Y, Drago-Garcia D Sci Signal. 2021; 14(688).

PMID: 34158398 PMC: 7614343. DOI: 10.1126/scisignal.abe6156.

Comparison of indirect peroxidase and avidin-biotin-peroxidase complex (ABC) immunohistochemical staining procedures for c-fos in rat brain.

Butler J, Barham B, Heidenreich B J Anat. 2019; 234(6):936-942.

PMID: 30861576 PMC: 6539692. DOI: 10.1111/joa.12967.

A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth.

Rothenberg D, Taliaferro J, Huber S, Begley T, Dedon P, White F iScience. 2018; 9:367-381.

PMID: 30466063 PMC: 6249402. DOI: 10.1016/j.isci.2018.11.004.

A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases.

Wang Y, Lee H, Hung M J Biomed Sci. 2018; 25(1):83.

PMID: 30449278 PMC: 6241042. DOI: 10.1186/s12929-018-0484-7.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M Mol Syst Biol. 2017; 13(5):928.

PMID: 28468958 PMC: 5448165. DOI: 10.15252/msb.20177554.

References

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

Courtneidge S, Azucena E, Pass I, Seals D, Tesfay L . The SRC substrate Tks5, podosomes (invadopodia), and cancer cell invasion. Cold Spring Harb Symp Quant Biol. 2006; 70:167-71. DOI: 10.1101/sqb.2005.70.014. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Mosesson Y, Mills G, Yarden Y . Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008; 8(11):835-50. DOI: 10.1038/nrc2521. View

Ransone L, Verma I . Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol. 1990; 6:539-57. DOI: 10.1146/annurev.cb.06.110190.002543. View

Egeblad M, Werb Z . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-74. DOI: 10.1038/nrc745. View

Shaul Y, Seger R . The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2006; 1773(8):1213-26. DOI: 10.1016/j.bbamcr.2006.10.005. View

Engelman J, Luo J, Cantley L . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-19. DOI: 10.1038/nrg1879. View

Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F . A module of negative feedback regulators defines growth factor signaling. Nat Genet. 2007; 39(4):503-12. DOI: 10.1038/ng1987. View

10.

Brennan S, Kuwano Y, Alkharouf N, Blackshear P, Gorospe M, Wilson G . The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 2009; 69(12):5168-76. PMC: 2724875. DOI: 10.1158/0008-5472.CAN-08-4238. View

11.

Hynes N, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2):177-84. DOI: 10.1016/j.ceb.2008.12.010. View

12.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

13.

Sparmann A, Bar-Sagi D . Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004; 6(5):447-58. DOI: 10.1016/j.ccr.2004.09.028. View

14.

Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U . Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem. 2007; 283(2):739-50. PMC: 2760391. DOI: 10.1074/jbc.M706287200. View

15.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

16.

Oikawa T, Itoh T, Takenawa T . Sequential signals toward podosome formation in NIH-src cells. J Cell Biol. 2008; 182(1):157-69. PMC: 2447888. DOI: 10.1083/jcb.200801042. View

17.

Keyse S . Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008; 27(2):253-61. DOI: 10.1007/s10555-008-9123-1. View

18.

Schulze A, Lehmann K, Jefferies H, McMahon M, Downward J . Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 2001; 15(8):981-94. PMC: 312671. DOI: 10.1101/gad.191101. View

19.

Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G . ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res. 2012; 72(11):2889-900. DOI: 10.1158/0008-5472.CAN-12-0212. View

20.

Perez-Soler R . The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res. 2004; 10(12 Pt 2):4238s-4240s. DOI: 10.1158/1078-0432.CCR-040017. View